Skip to main content
. 2018 Apr 29;97(9):1627–1632. doi: 10.1007/s00277-018-3329-2

Table 2.

Overview of literature

Number of articles 89
Number of individual cases 170
Sex, n (%) Male 74 (59.7%)
Female 50 (40.3%)
Not reported 46
Mean age 64.5 years
Mean time interval from diagnosis of CLL to neurological symptoms 32.3 months
Most common neurological symptomsa, allocated to CNS localisation of CLL, n (% of 125 patients with known symptoms) Symptoms unknown 45
No symptoms 2 (1.6%)
Symptoms attributed to cranial nerve palsy (any) 64 (51.2%)
- Diplopia (N. III/IV/VI) 22 (17.6%)
- Impaired vision (N. II) 22 (17.6%)
- Facial palsy (N. VII) 11 (8.8%)
- Impaired hearing 7 (5.6%)
- Impaired visual field 7 (5.6%)
- Dysarthria (N. V/VII/IX/X/XII) 6 (4.8%)
- Other 11 (8.8%)
Headache 30 (24.0%)
Altered mental state 19 (15.2%)
Cognitive decline 16 (12.8%)
Limb paralysis/paresis 15 (12.0%)
Impaired coordination of extremities 15 (12.0%)
Dizziness/vertigo 9 (7.2%)
Radiculopathy 8 (6.4%)
Other symptoms 81 (68.1.%)
Localisation of CLL, n (% of 120 patients with known localisation) Localisation unknown 50
Leptomeningeal 66 (55.0%)
Cerebral hemisphere 20 (16.7%)
Multiple sites 11 (9.2%)
Spinal cord or roots 9 (7.5%)
1 specific cranial nerve 7 (5.8%)
Hypophysis/pituitary gland 3 (2.5%)
Cerebellum 2 (1.7%)
Dural 1 (0.8%)
Brain stem 1 (0.8%)
Method of diagnosisb, n (% of 152 patients with known method of diagnosis) Method of diagnosis unknown 18
CSF 118 (77. 6%)
MRI brain or spinal cord 52 (34.2%)
Biopsy 30 (19.7%)
Obduction 13 (8.6%)
CT brain 11 (7.2%)

CLL chronic lymphocytic leukaemia, CNS central nervous system, CSF cerebrospinal fluid, MRI magnetic resonance imaging, CT computed tomography

aMultiple symptoms may be present in one patient

bMultiple methods may have been used in one patient